An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Trial Profile

An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate-017
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Jun 2017 Planned End Date changed from 21 May 2017 to 23 Jan 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results weighing and comparing cost and value of Nivolumab, Atezolizumab and Pembrolizumab vs. Docetaxel using patient data from KEYNOTE-010, POPLAR, Checkmate 057, Checkmate-017 and one other trial, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top